View Filing Data

Print Document View Excel Document

Document and Entity Information Document - shares	6 Months Ended
Document and Entity Information Document - shares	Jun. 30, 2015	Aug. 04, 2015
Document Information [Line Items]
Entity Registrant Name	Caladrius Biosciences, Inc.
Entity Central Index Key	0000320017
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-Q
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Common Stock, Shares Outstanding		55,349,712

Consolidated Balance Sheets - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Current Assets
Cash and cash equivalents	$ 36,211,324	$ 19,174,061
Marketable securities	3,011,693	7,080,053
Accounts receivable, net of allowance for doubtful accounts of $382,721 and $385,362 at June 30, 2015 and December 31, 2014, respectively	1,297,538	3,111,274
Deferred costs	2,973,487	2,566,989
Prepaid expenses and other current assets	3,980,547	4,349,167
Total current assets	47,474,589	36,281,544
Property, plant and equipment, net	16,811,639	15,960,731
Goodwill	25,209,336	25,209,336
Intangible assets, net	37,857,801	47,560,406
Other assets	1,271,381	1,263,375
Total assets	128,624,746	126,275,392
Current Liabilities
Accounts payable	2,266,337	5,661,173
Accrued liabilities	7,178,022	4,322,901
Long-term debt, current	1,361,148	1,109,612
Notes payable, current	882,696	816,776
Unearned revenues	4,643,033	4,334,120
Total current liabilities	16,331,236	16,244,582
Long-term Liabilities
Deferred income taxes	14,519,460	18,176,190
Notes payable	1,254,609	825,897
Long-term debt	13,638,852	13,890,388
Acquisition-related contingent consideration	13,460,000	18,260,000
Other long-term liabilities	3,467,248	804,546
Total liabilities	62,671,405	68,201,603
Commitments and Contingencies
Stockholders' Equity
Preferred stock, authorized, 20,000,000 shares; Series B convertible redeemable preferred stock liquidation value, 0.01 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at June 30, 2015 and December 31, 2014	100	100
Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 55,453,014 and 36,783,857 shares, at June 30, 2015 and December 31, 2014, respectively	55,453	36,784
Additional paid-in capital	394,589,826	350,428,903
Treasury stock, at cost	(705,742)	(705,742)
Accumulated deficit	(327,559,694)	(291,246,538)
Accumulated other comprehensive income	1,866	1,329
Total Caladrius Biosciences, Inc. stockholders' equity	66,381,809	58,514,836
Noncontrolling interests	(428,468)	(441,047)
Total equity	65,953,341	58,073,789
Liabilities and Equity, Total	$ 128,624,746	$ 126,275,392

Consolidated Balance Sheets (Parentheticals) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Preferred Stock, Shares Outstanding	10,000	10,000
Common Stock, Par Value	$ 0.001	$ 0.001
Accounts receivable trade, net of allowance for doubtful accounts	$ 382,721	$ 385,362
Preferred Stock, authorized	20,000,000	20,000,000
Common Stock, Shares, Outstanding	55,453,014	36,783,857
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Shares, Issued	55,453,014	36,783,857
Preferred stock, shares designated	825,000	825,000
Preferred stock, issued	10,000	10,000
Preferred stock, Series B convertible redeemable preferred stock liquidation value, share of common stock	0.01	0.01
Preferred stock, par value	$ 0.01	$ 0.01

Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
Consolidated Statements of Operations - USD ($)	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenues	$ 5,866,963	$ 4,488,932	$ 9,039,242	$ 8,544,507
Cost of revenues	5,798,796	3,677,355	9,167,408	7,503,370
Research and development	7,600,744	5,796,022	14,404,376	10,554,535
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	9,400,000	0	9,400,000	0
Selling, general, and administrative	8,736,373	7,446,017	19,824,272	16,416,032
Total operating costs and expenses	31,535,913	16,919,394	52,796,056	34,473,937
Operating loss	(25,668,950)	(12,430,462)	(43,756,814)	(25,929,430)
Other expense:
Other income (expense), net	5,354,845	(185,737)	4,808,818	(375,288)
Interest expense	(547,275)	(105,906)	(1,098,239)	(200,062)
Nonoperating Income (Expense), Total	4,807,570	(291,643)	3,710,579	(575,350)
Loss before (benefit) provision for income taxes and noncontrolling interests	(20,861,380)	(12,722,105)	(40,046,235)	(26,504,780)
(Benefit) provision for income taxes	(3,703,363)	47,387	(3,656,730)	94,796
Net loss	(17,158,017)	(12,769,492)	(36,389,505)	(26,599,576)
Less - loss attributable to noncontrolling interests	(31,757)	(164,474)	(76,349)	(312,502)
Net loss attributable to Caladrius Biosciences, Inc. common stockholders	$ (17,126,260)	$ (12,605,018)	$ (36,313,156)	$ (26,287,074)
Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders	$ (0.38)	$ (0.40)	$ (0.88)	$ (0.88)
Weighted average common shares outstanding	44,574,796	31,739,417	41,104,127	29,940,128

Consolidated Statements of Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
Consolidated Statements of Comprehensive Loss - USD ($)	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Net loss	$ (17,158,017)	$ (12,769,492)	$ (36,389,505)	$ (26,599,576)
Available for sale securities - net unrealized loss	1,866	998	537	998
Total other comprehensive loss	1,866	998	537	998
Comprehensive loss	(17,156,151)	(12,768,494)	(36,388,968)	(26,598,578)
Comprehensive loss attributable to noncontrolling interests	(31,757)	(164,474)	(76,349)	(312,502)
Comprehensive loss attributable to Caladrius Biosciences, Inc. common stockholders	$ (17,124,394)	$ (12,604,020)	$ (36,312,619)	$ (26,286,076)

Consolidated Statements of Equity - USD ($)	Total	Total NeoStem, Inc. Shareholders' Equity [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]	Noncontrolling Interest [Member]
Beginning Balance (shares) at Dec. 31, 2013			10,000	27,196,537
Beginning Balance at Dec. 31, 2013	$ 62,026,435	$ 62,542,475	$ 100	$ 27,197	$ 299,594,525	$ 0	$ (236,373,605)	$ (705,742)	$ (516,040)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(26,599,576)	(26,287,074)					(26,287,074)		(312,502)
Unrealized gain on marketable securities	998	998
Share-based compensation (in shares)				456,709
Share-based compensation	5,653,451	5,653,451		$ 457	5,652,994
Stock Issued During Period, Shares, New Issues				1,650,081
Net proceeds from issuance of common stock	10,149,438	10,149,438		$ 1,650	10,147,788
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period				41,136
Proceeds from exercise of options	230,183	230,183		$ 41	230,142
Proceeds from warrant exercise (in shares)				265,250
Stock Issued During Period, Value, Warrant Exercises	1,373,925	1,373,925		$ 264	1,373,661
Shares issued in CSC acquisition (shares)				5,329,510
Shares issued in CSC acquisition, amount	24,462,451	24,462,451		$ 5,330	24,457,121
Change in Ownership in Subsidiary	0	(86,618)			(86,618)				86,618
Ending Balance at Jun. 30, 2014	77,297,305	78,039,229	$ 100	$ 34,939	341,369,613	998	(262,660,679)	(705,742)	(741,924)
Ending Balance (shares) at Jun. 30, 2014			10,000	34,939,223
Beginning Balance (shares) at Dec. 31, 2014			10,000	36,783,857
Beginning Balance at Dec. 31, 2014	58,073,789	58,514,836	$ 100	$ 36,784	350,428,903	1,329	(291,246,538)	(705,742)	(441,047)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(36,389,505)	(36,313,156)					(36,313,156)		(76,349)
Unrealized gain on marketable securities	537	537				537
Share-based compensation (in shares)				903,337
Share-based compensation	8,132,106	8,132,106		$ 903	8,131,203
Stock Issued During Period, Shares, New Issues				17,765,820
Net proceeds from issuance of common stock	36,136,414	36,136,414		$ 17,766	36,118,648
Proceeds from exercise of options	0
Change in Ownership in Subsidiary	0	(88,928)			(88,928)				88,928
Ending Balance at Jun. 30, 2015	$ 65,953,341	$ 66,381,809	$ 100	$ 55,453	$ 394,589,826	$ 1,866	$ (327,559,694)	$ (705,742)	$ (428,468)
Ending Balance (shares) at Jun. 30, 2015			10,000	55,453,014

Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Jun. 30, 2015	Jun. 30, 2014
Payments to Acquire Marketable Securities	$ 3,013,157	$ 919,829
Cash flows from operating activities:
Net loss	(36,389,505)	(26,599,576)
Adjustments to reconcile net loss to net cash used in operating activities:
Equity-based compensation expense	8,132,106	5,653,451
Depreciation and amortization	1,254,305	987,698
Changes in fair value of derivative liability	0	23,175
Change in acquisition-related contingent consideration	(4,800,000)	400,000
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	9,400,000	0
Bad debt recovery	(2,641)	(2,020)
Deferred income taxes	(3,656,730)	94,796
Accretion Expense	33,054	0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	368,620	(944,297)
Accounts receivable	1,816,376	(602,132)
Deferred costs	(406,498)	(762,788)
Unearned revenues	308,912	1,013,946
Other assets	(8,005)	(106,909)
Accounts payable, accrued liabilities and other liabilities	2,122,987	(1,615,234)
Net cash used in operating activities	(21,827,019)	(22,506,240)
Cash flows from investing activities:
Proceeds from Sale and Maturity of Marketable Securities	7,049,000	0
Acquisition of property, plant and equipment	(1,802,607)	(2,439,266)
Net cash provided by (used in) investing activities	2,233,236	(3,308,201)
Cash Acquired from Acquisition	0	50,894
Cash flows from financing activities:
Proceeds from exercise of options	0	230,183
Proceeds from exercise of warrants	0	1,373,925
Net proceeds from issuance of common stock	36,136,414	10,149,439
Repayment of mortgage loan	0	(105,450)
Proceeds from notes payable	1,089,611	1,340,981
Repayment of notes payable	(594,979)	(443,325)
Net cash provided by financing activities	36,631,046	12,545,753
Net increase (decrease) in cash and cash equivalents	17,037,263	(13,268,688)
Cash and cash equivalents at beginning of period	19,174,061	46,133,759
Cash and cash equivalents at beginning of period	36,211,324	32,865,071
Cash paid during the period for:
Interest	744,811	196,200
Common stock and contingent consideration issued in merger	$ 0	$ 35,252,451

The Business

6 Months Ended

Jun. 30, 2015

The Business [Abstract]

Nature of Operations [Text Block]

The Business

Overview

Caladrius Biosciences, Inc. (“we,” “us”, "our", “Caladrius” or the “Company”) is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, and manufacturing. Caladrius is a company combining a leading cell therapy service provider with a development pipeline including late-stage clinical programs based on proprietary platform technology for immuno-oncology, as well as additional platform technologies for ischemic repair and immunomodulation. This integrated approach supports the industry in bringing significant life-improving medical treatments to market.

Our most advanced clinical program is based on our tumor cell/dendritic cell technology. It is focused on the development of an innovative cancer treatment (i.e., vaccine) that is designed to target the cells responsible for tumor growth and metastasis, known as cancer- or tumor-initiating cells ("CICs"), using purified CICs from a patient’s own tumor as an antigen source to induce or enhance an anti-tumor immune response in the patient. CLBS20, our lead product candidate based on this platform technology, targets malignant melanoma. CLBS20 is being studied in patients with recurrent Stage III or Stage IV metastatic melanoma. The program has been granted Fast Track and Orphan designation by the Food and Drug Administration (the "FDA") as well as Advanced Therapeutic Medicinal Product classification by the European Medicines Agency (the "EMA"). The protocol for the Phase 3 study, known as the Intus study, is the subject of a Special Protocol Assessment ("SPA") by the FDA. Our SPA letter states that our Phase 3 clinical trial is adequately designed to provide the necessary data that, depending on outcome, could support a Biologics License Application ("BLA") seeking marketing approval of CLBS20. The Intus Study is the subject of a $17.7 million grant from the California Institute for Regenerative Medicine, announced in May 2015. The study protocol calls for randomizing 250 patients. Patient screening began in the first quarter of 2015 and randomization of the first patient was announced in April 2015. An interim analysis is planned after 99 trial events (i.e., deaths) and is expected to occur during the fourth quarter of 2017. We are also evaluating other clinical indications for which we may advance this program, including ovarian, liver, colon, kidney, brain and lung cancers.

We are also developing therapies that are designed to utilize CD34 cells to regenerate tissue impacted by ischemia. Ischemia occurs when the supply of oxygenated blood in the body is restricted, causing local tissue distress and death. Ischemia can lead to conditions such as chronic heart failure ("CHF") and critical limb ischemia ("CLI"). We seek to improve oxygen delivery to affected tissues through the development and formation of new blood vessels. The ischemic repair program is supported by data from the clinical study of CLBS10, a product candidate designed to prevent heart failure and major adverse cardiac events following a severe heart attack (known as an ST segment elevation myocardial infarction ("STEMI")). After a thorough review, the Company has set the future direction for its ischemic repair program. Based on an analysis of the available Phase 2 data from the PreSERVE-AMI trial, an updated commercial assessment considering all major potential relevant cardiovascular indications and consultation with the Company’s new cardiovascular scientific advisory board and the Science and Technology Committee of the Board of Directors, Caladrius has decided that it will not pursue further development of CLBS10 upon completion of the ongoing PreSERVE-AMI Phase 2 clinical study. However, we believe that the positive suggestion of safety and therapeutic activity seen to date in the CLBS10 study supports the underlying platform technology and enables the Company’s exploration of what we believe to be more commercially viable indications of chronic heart failure (CLBS14) and/or critical limb ischemia (CLBS12) as targets for further development. In the case of CLI, we are actively exploring a program to develop CLBS12 in Japan under Japan’s regenerative medicine law. Japan’s regenerative medicine law enables an expedited path to conditional approval for regenerative medicine products that show sufficient safety evidence and signals of efficacy in a phase 2 study. This program is supported by three previous studies of autologous CD34 cells in no-option CLI patients. These other indications are early stage opportunities, and would require external funding and/or partnerships to proceed to the next step in clinical development.

We are also developing a therapy that is designed to utilize Regulatory T Cells ("Tregs") to treat diseases caused by imbalances in an individual's immune system. This novel approach seeks to restore immune balance by enhancing Treg cell number and function. Tregs are a natural part of the human immune system and regulate the activity of T effector cells, the cells that are responsible for protecting the body from viruses and other foreign antigens. When Tregs function properly, only harmful foreign materials are attacked by T effector cells. In autoimmune disease, it is thought that deficient Treg activity permits the T effector cells to attack the body's own tissues. We have received FDA concurrence that we may proceed to a Phase 2 study (the "Trutina study") of CLBS03, a Treg-based therapeutic being developed to treat type 1 diabetes mellitus ("T1DM") in adolescents. We are evaluating other clinical indications into which we may advance this program, including steroid-resistant asthma, multiple sclerosis, chronic obstructive pulmonary disease, inflammatory bowel disease, graft versus host disease, lupus, and rheumatoid arthritis.

We believe that cell-based therapies have the potential to create a paradigm change in the treatment for a variety of diseases and conditions and we are evaluating other programs that we view as holding particular promise, including an aesthetics program for a topical skin application and a very small embryonic like ("VSEL^TM") stem cell program for the treatment of retinal degeneration, bone restoration and wound healing. We have also received recent grants to support early stage research for retinal disease using human-induced pluripotent stem cells.

Through our wholly owned subsidiary, PCT, LLC, a Caladrius company ("PCT"), we are recognized as a world industry leader in providing high-quality innovative and reliable manufacturing capabilities and engineering solutions (e.g., process and assay development, optimization and automation) in the development of cell-based therapies. We currently operate three facilities qualified under Good Manufacturing Practices ("cGMPs") in Allendale, NJ, Mountain View, CA and Irvine, CA, and are positioned to expand our capacity both in the United States and internationally, as needed. In addition to leveraging this core expertise in the development of our own products, we partner opportunistically with other industry leaders who recognize our unique ability to significantly improve their manufacturing processes and supply clinical and commercial material.

We look forward to further advancement of our cell-based therapies to the market and to helping patients suffering from life-threatening medical conditions. Coupling our development expertise with our strong process development and manufacturing capability, we believe the stage is set for us to realize meaningful clinical development of our own proprietary platform technologies and manufacturing advancements, further positioning Caladrius as a leader in the immuno-oncology field and the cell therapy industry.

We anticipate requiring additional capital in order to fund the development of cell therapy product candidates and to grow the PCT business. To meet our short and long term liquidity needs, we currently expect to use existing cash and cash equivalents balances, our revenue generating activities, and a variety of other means, including our existing common stock purchase agreements with Aspire Capital. Other sources of liquidity could include additional potential issuances of debt or equity securities in public or private financings, additional warrant exercises, option exercises, partnerships and/or collaborations, and/or sale of assets. In addition, we will continue to seek as appropriate grants for scientific and clinical studies from various governmental agencies and foundations. We believe that our current cash, cash equivalents and marketable securities balances and revenue generating activities, along with access to funds under our agreement with Aspire Capital, will be sufficient to fund the business through the next 12 months. While we continue to seek capital through a number of means, there can be no assurance that additional financing will be available on acceptable terms, if at all. If we are unable to access capital necessary to meet our long-term liquidity needs, we may have to delay or discontinue the acquisition and development of cell therapies, and/or the expansion of our business or raise funds on terms that we currently consider unfavorable.

Basis of Presentation

The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“generally accepted accounting principles”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company’s financial position as of June 30, 2015 and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December 31, 2014, 2013 and 2012 included in our 2014 Form 10-K. Operating results for the six months ended June 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining the fair values of goodwill for potential goodwill impairments for our reporting units, fair values of In-Process R&D assets, fair values of acquisition-related contingent considerations, useful lives of our tangible and intangible assets, allowances for doubtful accounts, and stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.

An accounting policy is considered to be critical if it is important to the Company’s financial condition and results of operations and if it requires management’s most difficult, subjective and complex judgments in its application.

Principles of Consolidation

The Consolidated Financial Statements include the accounts of Caladrius Biosciences, Inc. and its wholly-owned and partially-owned subsidiaries and affiliates as listed below.



Entity	Percentage of Ownership	Location
Caladrius Biosciences, Inc.	100%	United States of America
NeoStem Therapies, Inc.	100%	United States of America
Stem Cell Technologies, Inc.	100%	United States of America
Amorcyte, LLC	100%	United States of America
PCT, LLC, a Caladrius Company	100%	United States of America
NeoStem Family Storage, LLC	100%	United States of America
Athelos Corporation (1)	96.9%	United States of America
PCT Allendale, LLC	100%	United States of America
NeoStem Oncology, LLC	100%	United States of America

(1) As of June 30, 2015, Becton Dickinson's ownership interest in Athelos was 3.1%.

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2015

Summary of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies [Text Block]

Summary of Significant Accounting Policies

In addition to the policies below, our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our 2014 Form 10-K. There were no changes to these policies during the six months ended June 30, 2015.

Cash and Cash Equivalents

Cash and cash equivalents include short-term, highly liquid, investments with maturities of 90 days or less when purchased.

Marketable Securities

The Company determines the appropriate classification of our marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of our marketable securities are considered as available-for-sale and carried at estimated fair values and reported in either cash equivalents or marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. We regularly review all of our investments for other-than-temporary declines in fair value. Our review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost basis. When we determine that the decline in fair value of an investment is below our accounting basis and this decline is other-than-temporary, we reduce the carrying value of the security we hold and record a loss for the amount of such decline.

Accounts Receivable

Accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts. The Company applies judgment in connection with establishing the allowance for doubtful accounts. Specifically, the Company analyzes the aging of accounts receivable balances, historical bad debts, customer concentration and credit-worthiness, current economic trends and changes in the Company’s customer payment terms. Significant changes in customer concentrations or payment terms, deterioration of customer credit-worthiness or weakening economic trends could have a significant impact on the collectability of the receivables and the Company’s operating results. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. Management regularly reviews the aging of receivables and changes in payment trends by its customers, and records a reserve when it believes collection of amounts due are at risk.

Deferred Costs

Deferred costs primarily represents costs incurred on in process projects at PCT that have not been completed. The Company reviews these projects periodically to determine that the value of each project is stated at the lower of cost or market.

Share-Based Compensation

The Company expenses all share-based payment awards to employees, directors, advisors and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Advisor and consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant.

Goodwill and Indefinite-Lived Intangible Assets

Goodwill is the excess of purchase price over the fair value of identified net assets of businesses acquired. Intangible assets with indefinite useful lives are measured at their respective fair values as of the acquisition date. The Company does not amortize goodwill and intangible assets with indefinite useful lives. Intangible assets related to in process research and development ("IPR&D") projects are considered to be indefinite-lived until the completion or abandonment of the associated R&D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time.

The Company reviews goodwill and indefinite-lived intangible assets at least annually, or at the time a triggering event is identified for possible impairment. Goodwill and indefinite-lived intangible assets are reviewed for possible impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit or the IPR&D below its carrying value. The Company tests its goodwill and indefinite-lived intangible assets each year on December 31. The Company reviews the carrying value of goodwill and indefinite-lived intangible assets utilizing an income approach model, and, where appropriate, a market value approach is also utilized to supplement the discounted cash flow model. The Company makes assumptions regarding estimated future cash flows, discount rates, long-term growth rates and market values to determine each reporting unit’s and IPR&D's estimated fair value. If these estimates or related assumptions change in the future, the Company may be required to record impairment charges. In accordance with its accounting policy, the Company tested goodwill for impairment as of December 31, 2014, 2013, and 2012 for its two reporting units as well as its IPR&D, and concluded there was no goodwill and IPR&D impairment. As of June 30, 2015, the Company determined that IPR&D valued at $9.4 million was fully impaired (see Note 8). The Company also tested goodwill for impairment as of June 30, 2015, since the IPR&D impairment was deemed a triggering event for goodwill impairment testing purposes, and concluded there was no goodwill impairment.

Definite-Lived Intangible Assets

Definite-lived intangible assets consist of customer lists, manufacturing technology, tradenames, patents and rights. These intangible assets are amortized on a straight line basis over their respective useful lives. The Company reviews definite-lived intangibles assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets. No triggering events were noted in the current period that would require interim impairment assessment.

Recognizing and Measuring Assets Acquired and Liabilities Assumed in Business Combinations at Fair Value

The Company accounts for acquired businesses using the purchase method of accounting, which requires that assets acquired and liabilities assumed be recorded at date of acquisition at their respective fair values. The consolidated financial statements and results of operations reflect an acquired business after the completion of the acquisition. The fair value of the consideration paid, including contingent consideration, is assigned to the underlying net assets of the acquired business based on their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. Amounts allocated to IPR&D are included on the balance sheet. Intangible assets, including IPR&D assets upon successful completion of the project and approval of the product, are amortized on a straight-line basis to amortization expense over the expected life of the asset. Significant judgments are used in determining the estimated fair values assigned to the assets acquired and liabilities assumed and in determining estimates of useful lives of long-lived assets. Fair value determinations and useful life estimates are based on, among other factors, estimates of expected future net cash flows, estimates of appropriate discount rates used to present value expected from future net cash flow streams, the timing of approvals for IPR&D projects and the timing of related product launch dates, the assessment of each asset’s life cycle, the impact of competitive trends on each asset’s life cycle and other factors. These judgments can materially impact the estimates used to allocate acquisition date fair values to assets acquired and liabilities assumed and the resulting timing and amount charged to, or recognized in current and future operating results. For these and other reasons, actual results may vary significantly from estimated results.

The Company determines the acquisition date fair value of contingent consideration obligations based on a probability-weighted income approach derived from revenue estimates, post-tax gross profit levels and a probability assessment with respect to the likelihood of achieving contingent obligations including contingent payments such as milestone obligations, royalty obligations and contract earn-out criteria, where applicable. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in fair value measurement accounting. The resulting probability-weighted cash flows are discounted using an appropriate effective annual interest rate. At each reporting date, the contingent consideration obligation will be revalued to estimated fair value at that time and changes in fair value will be reflected as income or expense in our consolidated statement of operations. Changes in the fair value of the contingent consideration obligations may result from changes in discount periods and rates, changes in the timing and amount of revenue estimates and changes in probability assumptions with respect to the likelihood of achieving the various contingent payment obligations. Changes in assumptions utilized in our contingent consideration fair value estimates could result in an increase or decrease in our contingent consideration obligation and a corresponding charge to operating loss or income.

Revenue Recognition

Clinical Services: The Company recognizes revenue for its (i) process development and (ii) clinical manufacturing services based on the terms of individual contracts.

We recognize revenues when all of the following conditions are met:


•	persuasive evidence of an arrangement exists;


•	delivery has occurred or the services have been rendered;


•	the fee is fixed or determinable; and


•	collectability is probable.

The Company considers signed contracts as evidence of an arrangement. The Company assesses whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the payment terms are subject to refund or adjustment. The Company assesses cash collectability based on a number of factors, including past collection history with the client and the client's creditworthiness. If the Company determines that collectability is not reasonably assured, it defers revenue recognition until collectability becomes reasonably assured, which is generally upon receipt of the cash. The Company's arrangements are generally non-cancellable, though clients typically have the right to terminate their agreement for cause if the Company materially fails to perform.

Revenues associated with process development services generally contain multiple stages that do not have stand-alone values and are dependent upon one another, and are recognized as revenue on a completed contract basis. Progress billings collected prior to contract completion are recorded as unearned revenue until such time the contract is completed, which usually requires formal client acceptance.

Clinical manufacturing services are generally distinct arrangements whereby the Company is paid for time and materials or for fixed monthly amounts. Revenue is recognized when efforts are expended or contractual terms have been met.

Some client agreements include multiple elements, comprised of process development and clinical manufacturing services. The Company believes that process development and clinical manufacturing services each have stand-alone value because these services can be provided separately by other companies. The Company (1) separates deliverables into separate units of accounting when deliverables are sold in a bundled arrangement and (2) allocates the arrangement's consideration to each unit in the arrangement based on its relative selling price.

Clinical Services Reimbursements: The Company separately charges the customers for the expenses associated with certain consumable resources (reimbursable expenses) that are specified in each clinical services contract. On a monthly basis, the Company bills customers for reimbursable expenses and immediately recognizes these billings as revenue, as the revenue is deemed earned as reimbursable expenses are incurred. For the three months ended June 30, 2015 and 2014, clinical services reimbursements were $0.9 million and $1.1 million, respectively. For the six months ended June 30, 2015 and 2014, clinical services reimbursements were $1.4 million and $1.8 million, respectively.

Processing and Storage Services: The Company recognizes revenue related to the collection and cryopreservation of autologous adult stem cells when the cryopreservation process is completed which is approximately 24 hours after cells have been collected. Revenue related to advance payments of storage fees is recognized ratably over the period covered by the advance payments.

Research and Development Costs

Research and development (R&D) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.

To further drive the Company’s cell therapy initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company’s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.

Recently Issued Accounting Pronouncement

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, "Revenue from Contracts with Customers (Topic 606)." The new revenue recognition standard provides a five-step analysis to determine when and how revenue is recognized. The standard requires that a company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This ASU is effective for annual periods beginning after December 15, 2017 and will be applied retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company is currently evaluating the impact of the pending adoption of ASU 2014-09 on its consolidated financial statements.

In August 2014, FASB issued ASU No. 2014-15 Preparation of Financial Statements - Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity's liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity's liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements - Liquidation Basis of Accounting. Even when an entity's liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity's ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the provisions in this ASU should be followed to determine whether to disclose information about the relevant conditions and events. The ASU is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the adoption of this ASU and its impact on the consolidated financial statements.

In April 2015, the FASB issued ASU 2015-03, which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This ASU requires retrospective adoption and will be effective for us beginning in our first quarter of 2017. Early adoption is permitted. We do not expect this adoption to have a material impact on our financial statements.

Acquisition

6 Months Ended

Jun. 30, 2015

Business Combinations [Abstract]

Mergers, Acquisitions and Dispositions Disclosures [Text Block]

Acquisition

On May 8, 2014, the Company closed (the “Closing”) its acquisition (the “CSC Acquisition”) of California Stem Cell, Inc. ("CSC"), pursuant to the terms of the Agreement and Plan of Merger, dated as of April 11, 2014 (the “Merger Agreement”), by and among the Company and its acquisition subsidiaries (collectively, "Subco"), CSC and Jason Livingston, solely in his capacity as CSC stockholder representative (together with his permitted successors, the “CSC Representative”). At Closing, Fortis Advisors LLC succeeded to the duties of the CSC Representative pursuant to the Merger Agreement. Pursuant to the Merger Agreement, on the Closing date, Subco was merged with CSC (the “Merger”), with Subco surviving the Merger as a wholly-owned subsidiary of the Company. At Closing, Subco changed its legal name to NeoStem Oncology, LLC.

Aggregate Merger Consideration

Pursuant to the terms of the Merger Agreement, all shares of CSC common stock (“CSC Common Stock”) and CSC preferred stock (“CSC Preferred Stock”, and collectively with the CSC Common Stock, the “CSC Capital Stock”) outstanding immediately prior to the Closing, and all outstanding unexercised options to purchase CSC Common Stock (“CSC Options”) (treated as if a net exercise had occurred), were canceled and converted into the right to receive, in the aggregate (and giving effect to the liquidation preferences accorded to the CSC Preferred Stock):

(1)An aggregate of 5,329,593 shares of the Company's common stock (subject to payment of nominal cash in lieu of fractional shares) (the “Closing Merger Consideration”).

(2)if payable after the Closing, certain payments in an amount of up to $90.0 million in the aggregate, payable in shares of the Company's common stock or cash, in the Company’s sole discretion, in the event of the successful completion of certain milestone events in connection with the CSC Acquisition (the “Milestone Payments”, and together with the Closing Merger Consideration, the “Merger Consideration”).

The fair value of the net assets acquired in the CSC Acquisition was $19.4 million. The fair value of the consideration paid by the Company was valued at $33.5 million, resulting in the recognition of goodwill in the amount of $14.1 million. The consideration paid was comprised of equity issued and milestone payments. The fair value of the equity issued by the Company was valued at $21.6 million. The fair value of the milestone payments was valued at $11.9 million, and is contingent on the achievement of certain milestones associated with the future development of the acquired programs. Such contingent consideration has been classified as a liability and will be subject to remeasurement at the end of each reporting period.

The fair value of assets acquired and liabilities assumed on May 8, 2014 is as follows (in thousands):



Cash and cash equivalents	$	51
Accounts receivable trade, net	45
Prepaids and other current assets	19
Property, plant and equipment, net	1,041
Other assets	201
Goodwill	14,092
In-Process R&D	34,290
Accounts payable	(333		)
Accrued liabilities	(2,014		)
Deferred tax liability	(13,901		)
Total	$	33,491

The total cost of the acquisition has been allocated to the assets acquired and the liabilities assumed based upon their estimated fair values at the date of the acquisition. The final allocation was completed during the measurement period which was one year from the date of acquisition.

Pro Forma Financial Information

The following supplemental table presents unaudited consolidated pro forma financial information as if the closing of the CSC Acquisition had occurred on January 1, 2014 (in thousands, except per share amounts):



	Three Months Ended June 30, 2014						Six Months Ended June 30, 2014
	(As Reported)			(Proforma)			(As Reported)			(Proforma)
Revenues	$	4,489		$	4,982		$	8,545		$	9,255
Net loss	$	(12,770	)	$	(13,574	)	$	(26,600	)	$	(29,097	)
Net loss attributable to Caladrius Biosciences, Inc.	$	(12,605	)	$	(13,409	)	$	(26,287	)	$	(28,784	)
Net loss per share attributable to Caladrius Biosciences, Inc.	$	(0.40	)	$	(0.36	)	$	(0.88	)	$	(0.82	)

The unaudited supplemental pro forma financial information should not be considered indicative of the results that would have occurred if the CSC Acquisition had been consummated on January 1, 2014, nor are they indicative of future results.

Available-for-Sale-Securities (Notes)

6 Months Ended

Jun. 30, 2015

Available-for-sale Securities [Abstract]

Cash, Cash Equivalents, and Marketable Securities [Text Block]

Available-for-Sale-Securities

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):



	June 30, 2015									December 31, 2014
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value		Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value
Certificate of deposits	$	—	$	—	$	—		$	—	$	249.0	$	—	$	—	$	249.0
Corporate debt securities	1,065.0		—		(1.8		)	1,063.2		—		—		—		—
Money market funds	11,635.0		—		—			11,635.0		12,791.9		—		—		12,791.9
Municipal debt securities	15,620.5		3.7		—			15,624.2		9,317.3		1.3		—		9,318.6
Total	$	28,320.5	$	3.7	$	(1.8	)	$	28,322.4	$	22,358.2	$	1.3	$	—	$	22,359.5

Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on our Consolidated Balance Sheets (in thousands):



	June 30, 2015		December 31, 2014
Cash and cash equivalents	$	25,310.7	$	15,279.4
Marketable securities	3,011.7		7,080.1
Total	$	28,322.4	$	22,359.5

The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands):



	June 30, 2015
	Amortized Cost		Estimated Fair Value
Less than one year	$	28,320.5	$	28,322.4
Greater than one year	—		—
Total	$	28,320.5	$	28,322.4

Deferred Costs	6 Months Ended
Deferred Costs	Jun. 30, 2015
Inventories [Abstract]
Deferred Costs	Deferred costs, representing work in process for costs incurred on process development contracts that have not been completed, were $3.0 million and $2.6 million as of June 30, 2015 and December 31, 2014, respectively. The Company also has deferred revenue of approximately $4.3 million and $3.9 million of advance billings received as of June 30, 2015 and December 31, 2014, respectively, related to these contracts.

Loss Per Share

6 Months Ended

Jun. 30, 2015

Loss Per Share [Abstract]

Loss Per Share [Text Block]

Loss Per Share

For the three and six months ended June 30, 2015 and 2014, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of loss per share as they are anti-dilutive. At June 30, 2015 and 2014, the Company excluded the following potentially dilutive securities:



	June 30,
	2015	2014
Stock Options	6,924,459	4,204,270
Warrants	3,518,952	3,623,956
Restricted Shares	281,054	205,231

Fair Value Measurements

6 Months Ended

Jun. 30, 2015

Fair Value Measurements [Abstract]

Fair Value Disclosures [Text Block]

Fair Value Measurements

The fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:

Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.

Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.

The Company classifies the fair value of the warrant derivative liabilities as Level 3 inputs. These inputs require material subjectivity because value is derived through the use of a lattice model that values the derivatives based on probability weighted discounted cash flows. In May 2014, the warrants expired and the value of the warrant derivative liabilities were written off and recorded in other expenses in our consolidated statement of operations.

The Company classifies the fair value of contingent consideration obligations as Level 3 inputs. The Company has recognized contingent consideration obligations related to the following:

•

In October 2011, in connection with the acquisition (the "Amorcyte Acquisition") of Amorcyte, LLC ("Amorcyte"), contingent consideration obligations were recognized relating to earn out payments equal to 10% of the net sales of the lead product candidate CLBS10 (in the event of and following the date of first commercial sale of CLBS10, a CD34 therapy), provided that in the event the Company sublicenses CLBS10, the applicable earn out payment will be equal to 30% of any sublicensing fees, and provided further that the Company will be entitled to recover direct out-of-pocket clinical development costs not previously paid or reimbursed and any costs, expenses, liabilities and settlement amounts arising out of claims of patent infringement or otherwise challenging Amorcyte’s right to use intellectual property, by reducing any earn out payments due by 50% until such costs have been recouped in full (the “Earn Out Payments”). As of June 30, 2015, based on a thorough analysis of the available data from the PreSERVE AMI Phase 2 clinical study for CLBS10, an updated commercial assessment, and consultation with the Company’s scientific advisory board and the Science and Technology Committee of the Board of Directors, the Company determined that it will not pursue further development of CLBS10. As a result, the Amorcyte Acquisition contingent consideration fair value decreased from $5.6 million to $0 as of June 30, 2015, since the contingent consideration is based solely on future revenues of CLBS10. The change in estimated fair value has been recorded in other income in our consolidated statement of operations.

•

In May 2014, in connection with the CSC Acquisition, contingent consideration obligations were recognized relating to milestone payments of up to $90.0 million, based on the achievement of certain milestones associated with the future development of the acquired programs. The contingent consideration fair value increased from $12.8 million as of December 31, 2014 to $13.5 million as of June 30, 2015. The change in estimated fair value is based on the impact of the time progression to reach those milestones as of June 30, 2015, and has been recorded in other expenses in our consolidated statement of operations.

The fair value of contingent consideration obligations is based on discounted cash flow models using a probability-weighted income approach. The measurements are based upon unobservable inputs supported by little or no market activity based on our own assumptions and experience. The Company bases the timing to complete the development and approval programs on the current development stage of the product and the inherent difficulties and uncertainties in developing a product candidate, such as obtaining FDA and other regulatory approvals. In determining the probability of regulatory approval and commercial success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period.

The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of June 30, 2015, and December 31, 2014 (in thousands):



	June 30, 2015								December 31, 2014
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Marketable securities - available for sale	$	—	$	3,011.7	$	—	$	3,011.7	$	—	$	7,080.0	$	—	$	7,080.0
	$	—	$	3,011.7	$	—	$	3,011.7	$	—	$	7,080.0	$	—	$	7,080.0

Liabilities:
Contingent consideration	$	—	$	—	$	13,460.0	$	13,460.0	$	—	$	—	$	18,260.0	$	18,260.0
	$	—	$	—	$	13,460.0	$	13,460.0	$	—	$	—	$	18,260.0	$	18,260.0

There were no transfers of financial instruments to or from Levels 1, 2 or 3 during the periods presented. For those financial instruments with significant Level 3 inputs, the following table summarizes the activity for the six months ended June 30, 2015 by type of instrument (in thousands):



	Six Months Ended
	June 30, 2015
	Contingent Consideration			Total
Beginning liability balance	$	18,260.0		$	18,260.0
Change in fair value recorded in operations	(4,800.0		)	(4,800.0		)
Ending liability balance	$	13,460.0		$	13,460.0

Some of the Company’s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate fair value due to their liquid or short-term nature, such as cash and cash equivalents, accounts receivable, and accounts payable. Our long-term debt and notes payable are carried at cost and approximate fair value due to their variable or fixed interest rates, which are consistent with the interest rates in the market.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Goodwill and Other Intangible Assets

6 Months Ended

Jun. 30, 2015

Goodwill and Other Intangible Assets [Abstract]

Goodwill and Intangible Assets [Text Block]

Goodwill and Other Intangible Assets

The Company's goodwill was $25.2 million as of June 30, 2015 and December 31, 2014.

The Company's intangible assets and related accumulated amortization as of June 30, 2015 and December 31, 2014 consisted of the following (in thousands):



		June 30, 2015							December 31, 2014
	Useful Life	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Customer list	10 years	$	1,000.0	$	(445.1	)	$	554.9	$	1,000.0	$	(395.1	)	$	604.9
Manufacturing technology	10 years	3,900.0		(1,735.9		)	2,164.1		3,900.0		(1,540.9		)	2,359.1
Tradename	10 years	800.0		(356.1		)	443.9		800.0		(316.1		)	483.9
In process R&D	Indefinite	34,290.0		—			34,290.0		43,690.0		—			43,690.0
Patent rights	19 years	669.0		(264.1		)	404.9		669.0		(246.5		)	422.5
Total Intangible Assets		$	40,659.0	$	(2,801.2	)	$	37,857.8	$	50,059.0	$	(2,498.6	)	$	47,560.4

The Company’s in process research and development ("IPR&D") programs were acquired in the Amorcyte Acquisition (CD34 technology) and CSC Acquisition (tumor cell/dendritic cell technology). With regards to the CD34 technology, the Company determined as of June 30, 2015, based on a thorough analysis of the available data from the PreSERVE AMI Phase 2 clinical study, an updated commercial assessment, and consultation with the Company’s scientific advisory board and the Science and Technology Committee of the Board of Directors, that it will not pursue further development of CLBS10 for the acute myocardial infarction indication upon completion of the ongoing PreSERVE AMI Phase 2 clinical study. However, it intends to explore other potential and more commercially viable indications of chronic heart failure and/or critical limb ischemia for its CD34 cell technology platform. These other indications are early stage opportunities, and would require external funding and/or partnerships to proceed to the next step in clinical development. As a result, and given the early stage and funding constraints of these other potential opportunities, the Company determined that IPR&D valued at $9.4 million was fully impaired as of June 30, 2015.

Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
Cost of revenue	$	74.7	$	78.7	$	153.9	$	158.4
Research and development	31.6		27.6		58.7		54.2
Selling, general and administrative	45.0		45.0		90.0		90.0
Total	$	151.3	$	151.3	$	302.6	$	302.6

Estimated intangible amortization expense on an annual basis for the succeeding five years is as follows (in thousands):



2015	$	302.6
2016	605.2
2017	605.2
2018	605.2
2019	605.2
Thereafter	35,134.4
Total	$	37,857.8

Accrued Liabilities

6 Months Ended

Jun. 30, 2015

Accrued Liabilities [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Accrued Liabilities

Accrued liabilities as of June 30, 2015 and December 31, 2014 were as follows (in thousands):



	June 30, 2015		December 31, 2014
Salaries, employee benefits and related taxes	$	3,459.1	$	2,807.2
Professional fees	735.9		495.4
California Institute of Regenerative Medicine advance funding - current	600.0		—
Other	2,383.0		1,020.3
Total	$	7,178.0	$	4,322.9

Debt

6 Months Ended

Jun. 30, 2015

Debt [Abstract]

Debt Disclosure [Text Block]

Debt

Notes Payable

As of June 30, 2015 and December 31, 2014, the Company had notes payable of approximately $2.1 million and $1.6 million, respectively. The notes relate to certain insurance policies and equipment financings, require monthly payments, and mature within one to three years.

Long-Term Debt

On September 26, 2014, the Company entered into a loan and security agreement (the “Loan and Security Agreement”) with Oxford Finance LLC (together with its successors and assigns, the “Lender”) pursuant to which the Lender has agreed to lend the Company up to $20.0 million. Upon entering into the Loan and Security Agreement, the Lender disbursed $15.0 million (“Term Loan A”). Under the terms of the Loan and Security Agreement, during the Second Draw Period (as defined below), the Company may, subject to certain conditions, borrow from Lender an additional $5.0 million (“Term Loan B”, together with Term Loan A, the “Term Loans”). The “Second Draw Period” is the period of time: (a) commencing on the date that Lender receives evidence in a form and substance satisfactory to Lender that the Company has entered into a strategic arrangement with respect to the Company’s CLBS10 product candidate for ST segment elevation myocardial infarction and receives an upfront payment of not less than $10.0 million in connection therewith, and (b) ending on the earlier of September 19, 2015 or the occurrence of an event of default under the Term Loans. After repayment of all outstanding amounts due under two loans from TD Bank, N.A. in the amount of approximately $3.1 million, and deductions for debt offering/issuance costs and interim period interest, the net proceeds from Term Loan A were $11.7 million. The debt offering/issuance costs have been recorded as debt issuance costs in other assets in the consolidated balance sheet, and will be amortized to interest expense throughout the life of the Term Loans using the effective interest rate method. The proceeds from the Term Loans may be used to satisfy the Company’s future working capital needs, including the development of its cell therapy product candidates.

The Company has been making interest-only payments on the outstanding amount of Term Loans on a monthly basis at a rate of 8.50% per annum. On April 29, 2015, with the Company's announcement that the first patient in the Intus Study had been randomized, the interest-only payment period on Term Loan A was extended from October 1, 2015 to April 1, 2016, which was in accordance with the Loan and Security Agreement. Commencing on April 1, 2016, the Company will make 30 consecutive monthly payments of principal and interest. The Term Loans mature on September 1, 2018. At its option, the Company may prepay all amounts owed under the Loan and Security Agreement (including all accrued and unpaid interest), subject to a prepayment fee that is determined based on the date the loan is prepaid. The Company is also required to pay Lender a final payment fee equal to 8% of the Term Loan A and Term Loan B (if disbursed). The final payment fee will be amortized to interest expense throughout the life of the Term Loans using the effective interest rate method. The Company paid a facility fee in the amount of $100,000 in connection with Term Loan A.

Under the Loan and Security Agreement and a related mortgage, the Company granted to Lender a security interest in all of the Company’s real property and personal property now owned or hereafter acquired, excluding intellectual property, and certain other assets and exemptions. The Company also entered into a Mortgage and Absolute Assignment of Leases and Rents (the "Mortgage"). The Company also granted Lender a security interest in the shares of the Company’s subsidiaries. The Loan and Security Agreement restricts the ability of the Company to: (a) convey, lease, sell, transfer or otherwise dispose of any part of its business or property; and (b) incur any additional indebtedness. The Loan and Security Agreement provides for standard indemnification of Lender and contains representations, warranties and certain covenants of the Company. Upon the occurrence of an event of default by the Company under the Loan and Security Agreement, Lender will have customary acceleration, collection and foreclosure remedies. There are no financial covenants associated to the Loan and Security Agreement. As of June 30, 2015, the Company was in compliance with all covenants under the Loan and Security Agreement.

Estimated future principal payments, interest, and fees due under the Loan and Security Agreement, assuming the Company does not draw down on the Term Loan B, are as follows:



Years Ending December 31,	(in millions)
2015	$	0.6
2016	5.3
2017	6.7
2018	6.2
Total	$	18.8

During the six months ended June 30, 2015, the Company recognized $0.6 million of interest expense related to the Loan and Security Agreement.

Shareholders' Equity

6 Months Ended

Jun. 30, 2015

Shareholders’ Equity [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

Shareholders' Equity

Equity Issuances

June 2015 Public Offering

In June 2015, the Company completed an underwritten offering of 12.5 million shares of the Company's common stock, at a public offering price of $2.00 per share. The underwriters also exercised their entire over-allotment option of 1.875 million shares. The Company received gross proceeds of $28.8 million, before deducting underwriting discounts and commissions and offering expenses payable by the Company.

Aspire Purchase Agreements

In May 2015, the Company entered into a common stock purchase agreement (the "2015 Purchase Agreement") with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”), which provides that, subject to certain terms and conditions, Aspire Capital is committed to purchase up to an aggregate of $30 million of shares (limited to a maximum of approximately 8.0 million shares, unless stockholder approval is obtained) of the Company's common stock over a 24-month term. As consideration for entering into the 2015 Purchase Agreement, the Company issued 364,837 shares of its common stock to Aspire Capital. As of June 30, 2015, the full amount was available to the Company under the 2015 Purchase Agreement. As of June 30, 2015, subject to the terms and conditions of the 2015 Purchase Agreement, we could sell to Aspire Capital the lesser of (i) $30 million of Common Stock or (ii) the dollar value of approximately 8.0 million shares of Common Stock based on the market price of the Common Stock at the time of such sale as determined under the 2015 Purchase Agreement.

In March 2014, the Company entered into a common stock purchase agreement (the “2014 Purchase Agreement”) with Aspire Capital, which provides that, subject to certain terms and conditions, Aspire Capital is committed to purchase up to an aggregate of $30.0 million worth of shares (limited to a maximum of approximately 5.7 million shares, unless shareholder approval is obtained) of the Company’s common stock over the 24-month term. As consideration for entering into the 2014 Purchase Agreement, the Company issued 150,000 shares of its common stock to Aspire Capital. During the six months ended June 30, 2015, the Company issued 3.0 million shares of common stock under the provisions of the 2014 Purchase Agreement with Aspire for gross proceeds of approximately $9.4 million. As of June 30, 2015, subject to the terms and conditions of the 2014 Purchase Agreement, we could sell to Aspire Capital the lesser of (i) $9.7 million of Common Stock or (ii) the dollar value of approximately 0.6 million shares of Common Stock based on the market price of the Common Stock at the time of such sale as determined under the 2014 Purchase Agreement.

At the Company’s discretion, it may present Aspire Capital with purchase notices under the 2015 Purchase Agreement or the 2014 Purchase Agreement (collectively, the "Purchase Agreements") from time to time to purchase the Company’s common stock, provided certain price and other requirements are met. The purchase price for the shares of stock is based upon one of two formulas set forth in the Purchase Agreements depending on the type of purchase notice the Company submits to Aspire Capital, and is based on market prices of the Company’s common stock (in the case of regular purchases) or a discount of 5% applied to volume weighted average prices (in the case of VWAP purchases), in each case as determined by parameters defined in the Purchase Agreements.

Stock Options and Warrants

The following table summarizes the activity for stock options and warrants for the six months ended June 30, 2015:



	Stock Options							Warrants
	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2014	4,427,234		$	9.19	6.93	$	28.6	3,550,956		$	14.12	2.12	$	1.0

Changes during the period:
Granted	2,903,188		$	3.31				—		$	—
Exercised	—		$	—				—		$	—
Forfeited	(103,513	)	$	6.52				—		$	—
Expired	(302,450	)	$	7.19				(32,004	)	$	19.37
Outstanding at June 30, 2015	6,924,459		$	6.86	7.77	$	—	3,518,952		$	14.07	1.65	$	—
Vested at June 30, 2015 or expected to vest in the future	6,616,000		$	7.00	7.69	$	—	3,518,952		$	14.07	1.65	$	—
Vested at June 30, 2015	4,726,752		$	8.00	7.12	$	—	3,516,452		$	14.07	1.64	$	—

Restricted Stock

During the six months ended June 30, 2015 and 2014, the Company issued restricted stock for services as follows (in thousands, except share data):



	Six Months Ended June 30,
	2015		2014
Number of Restricted Stock Issued	1,276,053		456,709
Value of Restricted Stock Issued	$	4,029.5	$	3,389.7

The weighted average estimated fair value of restricted stock issued for services in the six months ended June 30, 2015 and 2014 was $3.16 and $7.42 per share, respectively. The fair value of the restricted stock was determined using the Company’s closing stock price on the date of issuance.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

Share-Based Compensation (Notes)

6 Months Ended

Jun. 30, 2015

Share-based Compensation [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

Share-Based Compensation

Share-based Compensation

We utilize share-based compensation in the form of stock options, warrants and restricted stock. The following table summarizes the components of share-based compensation expense for the three and six months ended June 30, 2015 and 2014 (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
Cost of goods sold	$	378.2	$	98.5	$	495.1	$	236.6
Research and development	1,104.2		371.6		1,526.9		848.4
Selling, general and administrative	2,933.9		1,289.6		6,110.1		4,568.5
Total share-based compensation expense	$	4,416.3	$	1,759.7	$	8,132.1	$	5,653.5

Total compensation cost related to nonvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at June 30, 2015 were as follows (in thousands):



	Stock Options		Warrants		Restricted Stock
Unrecognized compensation cost	$	4,979.6	$	1.0	$	401.2
Expected weighted-average period in years of compensation cost to be recognized	3.29		0.05		2.93

Total fair value of shares vested and the weighted average estimated fair values of shares granted for the six months ended June 30, 2015 and 2014 were as follows (in thousands):



	Stock Options				Warrants
	Six Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
Total fair value of shares vested	$	4,915.3	$	2,552.2	$	14.0	$	15.0
Weighted average estimated fair value of shares granted	$	2.17	$	4.92	$	—	$	—

Valuation Assumptions

The fair value of stock options and warrants at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company’s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.

Research Funding	6 Months Ended
Research Funding	Jun. 30, 2015
Research and Development [Abstract]
Research Funding	Research Funding California Institute of Regenerative Medicine In June 2015, the California Institute of Regenerative Medicine ("CIRM") granted the Company a $17.7 million award (the "Award") to fund a significant portion of its Phase 3 Intus study for treating patients with recurrent Stage III or Stage IV metastatic melanoma. The Award provides for a $3.0 million project initiation payment, and $14.7 million in future operational milestone payments, and is subject to a dollar-for-dollar match funding by the Company. On June 30, 2015, the Company received the $3.0 million project initiation payment from CIRM, which will be amortized over the estimated Award period as a reduction to the related research and development expenses. Future operational milestone payments will be recorded as a reduction to research and development expenses when the milestone is achieved and payment is received or probable. The State of California has the right to receive, subject to the terms and conditions of the agreement between the Company and CIRM, future payments from the Company, or its collaborators, from sales of a commercial product resulting from research and development efforts supported by the grant, of up to nine times of the Award.

- Definition

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

+ References + Details

Income Taxes	6 Months Ended
Income Taxes	Jun. 30, 2015
Income Taxes [Abstract]
Income Tax Disclosure [Text Block]	Income Taxes As of December 31, 2014, the Company had approximately $177.2 million of Federal net operating loss carryforwards (NOLs) available to offset future taxable income expiring from 2025 through 2033. In accordance with Section 382 of the Internal Revenue code, the usage of the Company’s NOLs could be limited in the event of a change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible. If a change of ownership did occur there would be an annual limitation on the usage of the Company’s losses which are available through 2032. In assessing the ability to realize deferred tax assets, including the NOLs, the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets. Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time. Deferred tax liabilities were $14.5 million and $18.2 million as of June 30, 2015 and December 31, 2014, respectively, and relate to the taxable temporary differences on (i) the goodwill recognized in the PCT acquisition in 2011, (ii) the in-process R&D intangible asset recognized in the Amorcyte Acquisition in 2011, and (iii) the IPR&D intangible asset recognized in the CSC Acquisition in 2014. The taxable temporary difference associated with the goodwill, which is tax deductible and will be amortized over 15 years, will continue to increase the deferred tax liability balance over the amortization period, with an associated charge to the tax provision in each period. The deferred tax liabilities will only reverse when these indefinite-lived assets are sold, impaired, or reclassified from an indefinite-lived asset to a finite-lived asset. As of June 30, 2015, IPR&D recognized in the Amorcyte Acquisition and valued at $9.4 million was fully impaired (see Note 8), resulting in the reversal of the associated deferred tax liability of $3.7 million. As of June 30, 2015, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year. The Company's federal tax returns are currently being audited for the years 2012 and 2013. For years prior to 2011 the federal statute of limitations is closed for assessing tax. The Company’s state tax returns remain open to examination for a period of 3 to 4 years from date of filing. The Company ceased doing business in China in 2012. After 2012, the Company had no foreign tax filing obligations. The returns filed for 2012 and prior are subject to examination for 5 years.

Commitments and Contingencies

6 Months Ended

Jun. 30, 2015

Commitments and Contingencies [Abstract]

Commitments and Contingencies [Text Block]

Commitments and Contingencies

Lease Commitments

We entered into an assignment agreement with an unaffiliated third party, effective February 19, 2015, for general office space located in Basking Ridge, New Jersey. This property is used as the Company's corporate headquarters. The space is approximately 18,000 rentable square feet. Pursuant to the agreement, we are not obligated to make any payments for the space until January 2016.The base monthly rent during the period ending January 31, 2016 is currently $25,000 and the lease term ends July 31, 2020. In addition, there are two (2) five (5) year renewal options. In connection with the assumption of the lease, the third party (a) conveyed its rights in various scheduled furniture and equipment and (b) paid the Company approximately $580,000 which will offset the future rental payments to be paid by Caladrius until mid-2016. The amount paid to the Company included a security deposit of approximately $115,000.

The Company leases offices, of which certain have escalation clauses and renewal options, and also leases equipment under certain noncancelable operating leases that expire from time to time through 2021. In January 2014, the Company signed a new lease for a larger space at its New York office located at 420 Lexington Avenue, New York, NY 10170. The new lease extends through 2018. In connection with the CSC Acquisition, the Company assumed a facility lease in Irvine, California, with a termination at the end of 2017. We recently signed an amendment expanding our office space in Irvine by 4,000 square feet, and extending the term through 2021.

A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of June 30, 2015 are as follows (in thousands):



Years ended	Operating Leases
2015	$	985.7
2016	2,062.0
2017	1,863.8
2018	1,034.8
2019 and thereafter	1,949.6
Total minimum lease payments	$	7,895.9

Expense incurred under operating leases was approximately $0.4 million and $0.3 million for the three months ended June 30, 2015 and 2014, respectively. Expense incurred under operating leases was approximately $0.8 million and $0.5 million for the six months ended June 30, 2015 and 2014, respectively.

Contingencies

Under license agreements with third parties the Company is typically required to pay maintenance fees, make milestone payments and/or pay other fees and expenses and pay royalties upon commercialization of products. The Company also sponsors research at various academic institutions, which research agreements generally provide us with an option to license new technology discovered during the course of the sponsored research.

From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results.

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2015

Summary of Significant Accounting Policies [Abstract]

Schedule of Cash and Cash Equivalents [Table Text Block]

Cash and Cash Equivalents

Cash and cash equivalents include short-term, highly liquid, investments with maturities of 90 days or less when purchased.

Marketable Securities, Policy [Policy Text Block]

Marketable Securities

Receivables, Policy [Policy Text Block]

Accounts Receivable

Inventory Disclosure [Text Block]

Goodwill and Intangible Assets, Policy [Policy Text Block]

Goodwill and Indefinite-Lived Intangible Assets

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

Clinical Services: The Company recognizes revenue for its (i) process development and (ii) clinical manufacturing services based on the terms of individual contracts.

We recognize revenues when all of the following conditions are met:


•	persuasive evidence of an arrangement exists;


•	delivery has occurred or the services have been rendered;


•	the fee is fixed or determinable; and


•	collectability is probable.

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Issued Accounting Pronouncement

- Definition

Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.

+ References + Details

- Definition

Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.

+ References + Details

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References + Details

The Business (Tables)

6 Months Ended

Jun. 30, 2015

The Business [Abstract]

Subsidiary [Table Text Block]



Entity	Percentage of Ownership	Location
Caladrius Biosciences, Inc.	100%	United States of America
NeoStem Therapies, Inc.	100%	United States of America
Stem Cell Technologies, Inc.	100%	United States of America
Amorcyte, LLC	100%	United States of America
PCT, LLC, a Caladrius Company	100%	United States of America
NeoStem Family Storage, LLC	100%	United States of America
Athelos Corporation (1)	96.9%	United States of America
PCT Allendale, LLC	100%	United States of America
NeoStem Oncology, LLC	100%	United States of America

Acquisition (Tables)

6 Months Ended

Jun. 30, 2015

Business Combinations [Abstract]

Business Acquisition, Pro Forma Information [Table Text Block]



	Three Months Ended June 30, 2014						Six Months Ended June 30, 2014
	(As Reported)			(Proforma)			(As Reported)			(Proforma)
Revenues	$	4,489		$	4,982		$	8,545		$	9,255
Net loss	$	(12,770	)	$	(13,574	)	$	(26,600	)	$	(29,097	)
Net loss attributable to Caladrius Biosciences, Inc.	$	(12,605	)	$	(13,409	)	$	(26,287	)	$	(28,784	)
Net loss per share attributable to Caladrius Biosciences, Inc.	$	(0.40	)	$	(0.36	)	$	(0.88	)	$	(0.82	)

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

The fair value of assets acquired and liabilities assumed on May 8, 2014 is as follows (in thousands):



Cash and cash equivalents	$	51
Accounts receivable trade, net	45
Prepaids and other current assets	19
Property, plant and equipment, net	1,041
Other assets	201
Goodwill	14,092
In-Process R&D	34,290
Accounts payable	(333		)
Accrued liabilities	(2,014		)
Deferred tax liability	(13,901		)
Total	$	33,491

Available-for-Sale-Securities (Tables)

6 Months Ended

Jun. 30, 2015

Available-for-sale Securities [Abstract]

Schedule of Available-for-sale Securities Reconciliation [Table Text Block]

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):



	June 30, 2015									December 31, 2014
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value		Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value
Certificate of deposits	$	—	$	—	$	—		$	—	$	249.0	$	—	$	—	$	249.0
Corporate debt securities	1,065.0		—		(1.8		)	1,063.2		—		—		—		—
Money market funds	11,635.0		—		—			11,635.0		12,791.9		—		—		12,791.9
Municipal debt securities	15,620.5		3.7		—			15,624.2		9,317.3		1.3		—		9,318.6
Total	$	28,320.5	$	3.7	$	(1.8	)	$	28,322.4	$	22,358.2	$	1.3	$	—	$	22,359.5

Marketable Securities [Table Text Block]



	June 30, 2015		December 31, 2014
Cash and cash equivalents	$	25,310.7	$	15,279.4
Marketable securities	3,011.7		7,080.1
Total	$	28,322.4	$	22,359.5

Investments Classified by Contractual Maturity Date [Table Text Block]

The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands):



	June 30, 2015
	Amortized Cost		Estimated Fair Value
Less than one year	$	28,320.5	$	28,322.4
Greater than one year	—		—
Total	$	28,320.5	$	28,322.4

Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2015

Loss Per Share [Abstract]

ScheduleOfDilutiveSecuritiesExcludedFromComputationOfEarningsPerShare [Table Text Block]

At June 30, 2015 and 2014, the Company excluded the following potentially dilutive securities:



	June 30,
	2015	2014
Stock Options	6,924,459	4,204,270
Warrants	3,518,952	3,623,956
Restricted Shares	281,054	205,231

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2015

Fair Value Measurements [Abstract]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis, Valuation Techniques [Table Text Block]

•



	June 30, 2015								December 31, 2014
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Marketable securities - available for sale	$	—	$	3,011.7	$	—	$	3,011.7	$	—	$	7,080.0	$	—	$	7,080.0
	$	—	$	3,011.7	$	—	$	3,011.7	$	—	$	7,080.0	$	—	$	7,080.0

Liabilities:
Contingent consideration	$	—	$	—	$	13,460.0	$	13,460.0	$	—	$	—	$	18,260.0	$	18,260.0
	$	—	$	—	$	13,460.0	$	13,460.0	$	—	$	—	$	18,260.0	$	18,260.0

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

For those financial instruments with significant Level 3 inputs, the following table summarizes the activity for the six months ended June 30, 2015 by type of instrument (in thousands):



	Six Months Ended
	June 30, 2015
	Contingent Consideration			Total
Beginning liability balance	$	18,260.0		$	18,260.0
Change in fair value recorded in operations	(4,800.0		)	(4,800.0		)
Ending liability balance	$	13,460.0		$	13,460.0

Goodwill and Other Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2015

Goodwill and Other Intangible Assets [Abstract]

Schedule of Goodwill [Table Text Block]

The Company's goodwill was $25.2 million as of June 30, 2015 and December 31, 2014.

Schedule of Finite-Lived Intangible Assets by Major Class [Table Text Block]

The Company's intangible assets and related accumulated amortization as of June 30, 2015 and December 31, 2014 consisted of the following (in thousands):



		June 30, 2015							December 31, 2014
	Useful Life	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Customer list	10 years	$	1,000.0	$	(445.1	)	$	554.9	$	1,000.0	$	(395.1	)	$	604.9
Manufacturing technology	10 years	3,900.0		(1,735.9		)	2,164.1		3,900.0		(1,540.9		)	2,359.1
Tradename	10 years	800.0		(356.1		)	443.9		800.0		(316.1		)	483.9
In process R&D	Indefinite	34,290.0		—			34,290.0		43,690.0		—			43,690.0
Patent rights	19 years	669.0		(264.1		)	404.9		669.0		(246.5		)	422.5
Total Intangible Assets		$	40,659.0	$	(2,801.2	)	$	37,857.8	$	50,059.0	$	(2,498.6	)	$	47,560.4

Schedule of Amortization Expense [Table Text Block]

Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
Cost of revenue	$	74.7	$	78.7	$	153.9	$	158.4
Research and development	31.6		27.6		58.7		54.2
Selling, general and administrative	45.0		45.0		90.0		90.0
Total	$	151.3	$	151.3	$	302.6	$	302.6

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Estimated intangible amortization expense on an annual basis for the succeeding five years is as follows (in thousands):



2015	$	302.6
2016	605.2
2017	605.2
2018	605.2
2019	605.2
Thereafter	35,134.4
Total	$	37,857.8

Accrued Liabilities Accrued Liabilities (Tables)

6 Months Ended

Jun. 30, 2015

Accrued Liabilities [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

Accrued liabilities as of June 30, 2015 and December 31, 2014 were as follows (in thousands):



	June 30, 2015		December 31, 2014
Salaries, employee benefits and related taxes	$	3,459.1	$	2,807.2
Professional fees	735.9		495.4
California Institute of Regenerative Medicine advance funding - current	600.0		—
Other	2,383.0		1,020.3
Total	$	7,178.0	$	4,322.9

Debt Long term debt (Tables)

6 Months Ended

Jun. 30, 2015

Long-term Debt, Unclassified [Abstract]

Schedule of Maturities of Long-term Debt [Table Text Block]

Estimated future principal payments, interest, and fees due under the Loan and Security Agreement, assuming the Company does not draw down on the Term Loan B, are as follows:



Years Ending December 31,	(in millions)
2015	$	0.6
2016	5.3
2017	6.7
2018	6.2
Total	$	18.8

Shareholders' Equity (Tables)

6 Months Ended

Jun. 30, 2015

Shareholders’ Equity [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

The following table summarizes the activity for stock options and warrants for the six months ended June 30, 2015:



	Stock Options							Warrants
	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2014	4,427,234		$	9.19	6.93	$	28.6	3,550,956		$	14.12	2.12	$	1.0

Changes during the period:
Granted	2,903,188		$	3.31				—		$	—
Exercised	—		$	—				—		$	—
Forfeited	(103,513	)	$	6.52				—		$	—
Expired	(302,450	)	$	7.19				(32,004	)	$	19.37
Outstanding at June 30, 2015	6,924,459		$	6.86	7.77	$	—	3,518,952		$	14.07	1.65	$	—
Vested at June 30, 2015 or expected to vest in the future	6,616,000		$	7.00	7.69	$	—	3,518,952		$	14.07	1.65	$	—
Vested at June 30, 2015	4,726,752		$	8.00	7.12	$	—	3,516,452		$	14.07	1.64	$	—

Restricted Stock [Table Text Block]

During the six months ended June 30, 2015 and 2014, the Company issued restricted stock for services as follows (in thousands, except share data):



	Six Months Ended June 30,
	2015		2014
Number of Restricted Stock Issued	1,276,053		456,709
Value of Restricted Stock Issued	$	4,029.5	$	3,389.7

Share-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2015

Share-based Compensation [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

The following table summarizes the components of share-based compensation expense for the three and six months ended June 30, 2015 and 2014 (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
Cost of goods sold	$	378.2	$	98.5	$	495.1	$	236.6
Research and development	1,104.2		371.6		1,526.9		848.4
Selling, general and administrative	2,933.9		1,289.6		6,110.1		4,568.5
Total share-based compensation expense	$	4,416.3	$	1,759.7	$	8,132.1	$	5,653.5

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]



	Stock Options		Warrants		Restricted Stock
Unrecognized compensation cost	$	4,979.6	$	1.0	$	401.2
Expected weighted-average period in years of compensation cost to be recognized	3.29		0.05		2.93

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]

Total fair value of shares vested and the weighted average estimated fair values of shares granted for the six months ended June 30, 2015 and 2014 were as follows (in thousands):



	Stock Options				Warrants
	Six Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
Total fair value of shares vested	$	4,915.3	$	2,552.2	$	14.0	$	15.0
Weighted average estimated fair value of shares granted	$	2.17	$	4.92	$	—	$	—

Valuation Assumptions

Commitments and Contingencies (Tables)

6 Months Ended

Jun. 30, 2015

Commitments and Contingencies [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of June 30, 2015 are as follows (in thousands):



Years ended	Operating Leases
2015	$	985.7
2016	2,062.0
2017	1,863.8
2018	1,034.8
2019 and thereafter	1,949.6
Total minimum lease payments	$	7,895.9

The Business (Details) - USD ($)	6 Months Ended
The Business (Details) - USD ($)	Jun. 30, 2015	Jun. 30, 2014
The Company [Line Items]
Subsidiary, Ownership Interest by Parent	96.90%
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	3.10%
Change in Ownership in Subsidiary	$ 0	$ 0
Noncontrolling Interest [Member]
The Company [Line Items]
Change in Ownership in Subsidiary	$ 88,928	$ 86,618
NeoStem, Inc. [Member]
The Company [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%

The Business Principal of consolidation (Details)	Jun. 30, 2015
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	96.90%
NeoStem, Inc. [Member]
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
NeoStem Therapies, Inc [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
Stem Cell Technologies, Inc [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
Amorcyte, LLC [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
Progenitor Cell Therapy, LLC [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
NeoStem Family Storage, LLC [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
PCT Allendale, LLC [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
NeoStem Oncology [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Summary of Significant Accounting Policies [Abstract]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	$ 9,400,000	$ 0	$ 9,400,000	$ 0
Clinical Services Reimbursement	$ 900,000	$ 1,100,000	$ 1,400,000	$ 1,800,000

Acquisition (Details) - USD ($)	3 Months Ended		6 Months Ended
Acquisition (Details) - USD ($)	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	May 08, 2014
Business Acquisition [Line Items]
Change in acquisition-related contingent consideration			$ (4,800,000)	$ 400,000
Revenues	$ 5,866,963	$ 4,488,932	9,039,242	8,544,507
Net loss	$ (17,158,017)	$ (12,769,492)	$ (36,389,505)	(26,599,576)
Common Stock, Shares, Issued	55,453,014		55,453,014		36,783,857	5,329,593
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High						$ 90,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net						19,400,000
Acquisition-related contingent consideration	$ 13,460,000		$ 13,460,000		$ 18,260,000	11,900,000
Business Acquisition, Transaction Costs						33,500,000
Cash and cash equivalents						51,000
Accounts receivable, net of allowance for doubtful accounts of $390,118 and $391,829 at March 31, 2014 and December 31, 2013, respectively						45,000
Prepaid expenses and other current assets						19,000
Property, plant and equipment, net						1,041,000
Other assets						201,000
Goodwill	$ 25,209,336		25,209,336		$ 25,209,336	14,092,000
Equity Issued in Business Combination, Fair Value Disclosure						21,600,000
Intangible assets, net						34,290,000
Accounts Payable, Current						(333,000)
Accrued Liabilities, Current						(2,014,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent						(13,901,000)
Deferred Tax Liabilities, Net, Noncurrent			$ 3,656,730	$ (94,796)
Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders	$ (0.38)	$ (0.40)	$ (0.88)	$ (0.88)
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net						$ 33,491,000
NeoStem Oncology [Member]
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Revenue		$ 4,982,000		$ 9,255,000
Business Acquisition, Pro Forma Net Income (Loss)		(13,574,000)		(29,097,000)
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual		$ (13,409,000)		$ (28,784,000)
Business Acquisition, Pro Forma Earnings Per Share, Diluted		$ (0.36)		$ (0.82)
NeoStem, Inc. [Member]
Business Acquisition [Line Items]
Revenues		$ 4,489,000		$ 8,545,000
Net loss		(12,770,000)		(26,600,000)
Net Income (Loss) Attributable to Parent		$ (12,605,000)		$ (26,287,000)
Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders		$ (0.40)		$ (0.88)

Available-for-Sale-Securities Schedule of Available-for-sale Securites Reconciliation (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	$ 28,320,500	$ 22,358,200
Deferred Tax Liabilities, Unrealized Gains on Trading Securities	3,700	1,300
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	(1,800)	0
Certificates of Deposit, at Carrying Value	28,322,400	22,359,500
Certificates of Deposit [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	0	249,000
Deferred Tax Liabilities, Unrealized Gains on Trading Securities	0	0
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	0	0
Certificates of Deposit, at Carrying Value	0	249,000
Corporate Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	1,065,000	0
Deferred Tax Liabilities, Unrealized Gains on Trading Securities	0	0
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	(1,800)	0
Certificates of Deposit, at Carrying Value	1,063,200	0
Money Market Funds [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	11,635,000	12,791,900
Deferred Tax Liabilities, Unrealized Gains on Trading Securities	0	0
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	0	0
Certificates of Deposit, at Carrying Value	11,635,000	12,791,900
Municipal Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	15,620,500	9,317,300
Deferred Tax Liabilities, Unrealized Gains on Trading Securities	3,700	1,300
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	0	0
Certificates of Deposit, at Carrying Value	$ 15,624,200	$ 9,318,600

Available-for-Sale-Securities Classification of the available-for-sale securities (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Available-for-sale Securities [Abstract]
Cash	$ 25,310,700	$ 15,279,400
Marketable securities	3,011,700	7,080,100
Total	$ 28,322,400	$ 22,359,500

Available-for-Sale-Securities Available-for-sale Securities by Contractual Maturity (Details)	Jun. 30, 2015 USD ($)
Available-for-sale Securities [Abstract]
Available-for-sale Securities, Debt Maturities, Year Two Through Five, Amortized Cost Basis	$ 0
Available-for-sale Securities, Debt Maturities, Remainder of Fiscal Year, Amortized Cost Basis	28,322,400
Available-for-sale Securities, Noncurrent	0
Amortized Cost	28,320,500
Estimated Fair Value	$ 28,322,400

- Definition

Investments in debt and equity securities which are categorized neither as held-to-maturity nor trading and which are intended to be sold or mature more than one year from the balance sheet date or operating cycle, if longer. Such securities are reported at fair value; unrealized gains (losses) related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain (loss) of an Available-for-sale security that is designated as being hedged in a fair value hedge is recognized in earnings during the period of the hedge, as are other than temporary declines in fair value below the cost basis for investments in equity securities and debt securities that an entity intends to sell or it is more likely than not that it will be required to sell before the recovery of its amortized cost basis. Other than temporary declines in fair value below the cost basis for debt securities categorized as Available-for-sale that an entity does not intend to sell and for which it is not more likely than not that the entity will be required to sell before the recovery of its amortized cost basis are bifurcated into credit losses and losses related to all other factors. Other than temporary declines in fair value below cost basis related to credit losses are recognized in earnings, and losses related to all other factors are recognized in other comprehensive income.

+ References + Details

Deferred Costs (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Schedule of Inventory [Line Items]
Deferred costs	$ 2,973,487	$ 2,566,989
Multiple Stage Contracts [Member]
Schedule of Inventory [Line Items]
Deferred Revenue	$ 4,300,000	$ 3,900,000

Loss Per Share (Details) - shares	6 Months Ended
Loss Per Share (Details) - shares	Jun. 30, 2015	Jun. 30, 2014
Warrants
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	3,518,952	3,623,956
Stock Options [Member]
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	6,924,459	4,204,270
Restricted Stock [Member]
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	281,054	205,231

Fair Value Measurements Fair value hierarchy the Company’s financial assets and liabilities (Details) - USD ($)	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	May 08, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Acquisition-related contingent consideration	$ 13,460,000		$ 18,260,000	$ 11,900,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High				$ 90,000,000
Accrued Liabilities and Other Liabilities	13,460,000		18,260,000
Business Combination, Liabilities Arising from Contingencies, Amount Recognized	13,500,000		12,800,000
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent Consideration Classified as Equity, Fair Value Disclosure	0		0
Accrued Liabilities and Other Liabilities	0		0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent Consideration Classified as Equity, Fair Value Disclosure	0		0
Accrued Liabilities and Other Liabilities	0		0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent Consideration Classified as Equity, Fair Value Disclosure	13,460,000		18,260,000
Accrued Liabilities and Other Liabilities	13,460,000		18,260,000
Contingent Consideration Classified as Equity [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Acquisition-related contingent consideration	13,460,000		18,260,000
Amorcyte, LLC [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Acquisition-related contingent consideration	0	$ 5,600,000
Contingent Consideration Classified as Equity [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent Consideration Classified as Equity, Fair Value Disclosure	$ 13,460,000		$ 18,260,000

Fair Value Measurements Financial instruments with significant Level 3 inputs (Details) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Mar. 31, 2015	Dec. 31, 2014	May 08, 2014	Oct. 31, 2011
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	$ 3,011,700			$ 7,080,000
Percentage of Net Sales						10.00%
Percentage of license cost						30.00%
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Acquisition-related contingent consideration	13,460,000			18,260,000	$ 11,900,000
Accrued Liabilities and Other Liabilities	13,460,000			18,260,000
Change in acquisition-related contingent consideration	(4,800,000)	$ 400,000
Fair Value, Option, Changes in Fair Value, Gain (Loss)	(4,800,000)
Contingent Consideration Classified as Equity [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Acquisition-related contingent consideration	13,460,000			18,260,000
Change in acquisition-related contingent consideration	(4,800,000)
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0			0
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Accrued Liabilities and Other Liabilities	0			0
Contingent Consideration Classified as Equity, Fair Value Disclosure	0			0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	3,011,700			7,080,000
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Accrued Liabilities and Other Liabilities	0			0
Contingent Consideration Classified as Equity, Fair Value Disclosure	0			0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0			0
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Accrued Liabilities and Other Liabilities	13,460,000			18,260,000
Contingent Consideration Classified as Equity, Fair Value Disclosure	13,460,000			$ 18,260,000
Amorcyte, LLC [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Acquisition-related contingent consideration	$ 0		$ 5,600,000

Goodwill and Other Intangible Assets Intangible Assets and Related Accumulated Amortization (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	$ 9,400,000	$ 0	$ 9,400,000	$ 0
Goodwill [Roll Forward]
Goodwill	25,209,336		25,209,336
Finite-Lived Intangible Assets, Gross	40,659,000		40,659,000		$ 50,059,000
Finite-Lived Intangible Assets, Accumulated Amortization	(2,801,200)		(2,801,200)		(2,498,600)
Finite-Lived Intangible Assets, Future Amortization Expense	37,857,800		37,857,800		47,560,400
Customer Lists [Member]
Goodwill [Roll Forward]
Finite-Lived Intangible Assets, Gross	1,000,000		1,000,000		1,000,000
Finite-Lived Intangible Assets, Accumulated Amortization	(445,100)		(445,100)		(395,100)
Finite-Lived Intangible Assets, Future Amortization Expense	554,900		$ 554,900		604,900
Finite-Lived Intangible Assets, Useful Life			10 years
Manufacturing Technology [Member]
Goodwill [Roll Forward]
Finite-Lived Intangible Assets, Gross	3,900,000		$ 3,900,000		3,900,000
Finite-Lived Intangible Assets, Accumulated Amortization	(1,735,900)		(1,735,900)		(1,540,900)
Finite-Lived Intangible Assets, Future Amortization Expense	2,164,100		$ 2,164,100		2,359,100
Finite-Lived Intangible Assets, Useful Life			10 years
Trade Names [Member]
Goodwill [Roll Forward]
Finite-Lived Intangible Assets, Gross	800,000		$ 800,000		800,000
Finite-Lived Intangible Assets, Accumulated Amortization	(356,100)		(356,100)		(316,100)
Finite-Lived Intangible Assets, Future Amortization Expense	443,900		$ 443,900		483,900
Finite-Lived Intangible Assets, Useful Life			10 years
In Process R and D [Member]
Goodwill [Roll Forward]
Finite-Lived Intangible Assets, Gross	34,290,000		$ 34,290,000		43,690,000
Finite-Lived Intangible Assets, Accumulated Amortization	0		0		0
Finite-Lived Intangible Assets, Future Amortization Expense	34,290,000		34,290,000		43,690,000
VSEL Patent Rights [Member]
Goodwill [Roll Forward]
Finite-Lived Intangible Assets, Gross	669,000		669,000		669,000
Finite-Lived Intangible Assets, Accumulated Amortization	(264,100)		(264,100)		(246,500)
Finite-Lived Intangible Assets, Future Amortization Expense	$ 404,900		$ 404,900		$ 422,500
Finite-Lived Intangible Assets, Useful Life			19 years

Goodwill and Other Intangible Assets Intangible Amortization Expense (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 151,300	$ 151,300	$ 302,600	$ 302,600
Cost of revenue
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	74,700	78,700	153,900	158,400
Research and development
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	31,600	27,600	58,700	54,200
Selling, general and administrative
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 45,000	$ 45,000	$ 90,000	$ 90,000

Goodwill and Other Intangible Assets Goodwill (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Goodwill [Abstract]
Goodwill	$ 25,200,000
Future Amortization Expense, Year One	302,600
Future Amortization Expense, Year Two	605,200
Future Amortization Expense, Year Three	605,200
Future Amortization Expense, Year Four	605,200
Future, Amortization Expense, Year Five	605,200
Thereafter	35,134,400
Finite-Lived Intangible Assets, Future Amortization Expense	$ 37,857,800	$ 47,560,400

Accrued Liabilities Accrued Liabilities (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Accrued Liabilities [Abstract]
Salaries, employee benefits and related taxes	$ 3,459,100	$ 2,807,200
Professional fees	735,900	495,400
Other	2,383,000	1,020,300
Accrued Liabilities	7,178,000	4,322,900
Funds Held for Clients	$ 600,000	$ 0

Debt (Details) - USD ($)	6 Months Ended
Debt (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014	Sep. 26, 2014
Debt Instrument [Line Items]
Notes Payable	$ 2,100,000	$ 1,600,000
Mortgages payable			$ 20,000,000
Debt Instrument, Periodic Payment	10,000,000
Proceeds from Issuance of Debt	11,700,000
Debt Issuance Cost	(100,000)
Mortgage Loans on Real Estate, Carrying Amount of Mortgages	3,100,000
Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Two	600,000
Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Three	5,300,000
Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Four	6,700,000
Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Five	6,200,000
Long-term Debt	18,800,000
Interest expense	$ 600,000
Impaired Long-Lived Assets Held and Used, Asset Name [Domain]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Interest	8.00%
Long-term Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum	8.50%
Aspire Capital Purchase Agreement [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross			15,000,000
NeoStem, Inc. [Member] \| Long-term Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Payment Terms	30 months
License Agreement Terms [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross			$ 5,000,000

Shareholders' Equity Equity Issuances (Details) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	May 01, 2015	Dec. 31, 2014	May 08, 2014
Class of Stock [Line Items]
Common Stock, Shares, Issued	55,453,014			36,783,857	5,329,593
Net proceeds from issuance of common stock	$ 36,136,414	$ 10,149,438
Common Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Other	12,500,000
Fair Value Inputs, Offered Quotes	$ 2.00
Net proceeds from issuance of common stock	$ 28,800,000
Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Term of agreement in months	24 months	24 months
Discount Applied To Weighted Average Price		5.00%
Purchase Commitment, Remaining Minimum Amount Committed	$ 9,700,000
Stock Issued During Period, Shares, Other	7,990,123	5,687,942
Stock Issued During Period, Shares, New Issues	3,000,000
Net proceeds from issuance of common stock	$ 9,400,000
Over-Allotment Option [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Other	1,875,000
Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Common Stock, Shares, Issued	364,837	150,000
Purchase Commitment, Remaining Minimum Amount Committed		$ 30,000,000	$ 30,000,000
Common Stock, Capital Shares Reserved for Future Issuance		600,000

Shareholders' Equity Stock options and warrants (Details)	6 Months Ended	12 Months Ended
	Jun. 30, 2015 USD ($) $ / shares $ / warrant shares	Dec. 31, 2014 USD ($) $ / shares $ / warrant shares
Stock Options and Warrants [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value \| $	$ 0	$ 28,600
Common Stock Warrants, Shares	3,518,952	3,550,956
Weighted Average Exercise Price, Warrants Outstanding \| $ / warrant	14.07	14.12
Weighted Average Remaining Contractual Term warrant outstanding	1 year 7 months 24 days	2 years 1 month 13 days
Aggregate Intrinsic Value, Warrants Outstanding \| $	$ 0	$ 1,000
Warrants Granted	0
Warrants Canceled	32,004
Weighted Average Exercise Price, Warrants Granted \| $ / shares	$ 0.00
Warrants Exercised	0
Weighted Average Exercise Price, Warrants Exercised \| $ / shares	$ 0.00
Warrants Expired	0
Weighted Average Exercise Price, Warrants Expired \| $ / shares	$ 0.00
Weighted Average Exercise Price, Warrants Canceled \| $ / shares	$ 19.37
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value \| $	$ 0
shares, vested and expected to vest	3,518,952
Weighted Average Exercise Price, Warrants vested & expected to vest \| $ / warrant	14.07
Aggregate Intrinsic Value, Warrants vested and expected to vest \| $	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value \| $	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	3,516,452
Weighted Average Exercise Price, Warrants Exercisable \| $ / warrant	14.07
weighted Average Remaining Contractual Term, warrants vested	1 year 7 months 21 days
Aggregate Intrinsic Value, Warrants vested \| $	$ 0
US Equity Plan [Member]
Stock Options and Warrants [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	6,924,459	4,427,234
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price \| $ / shares	$ 6.86	$ 9.19
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	7 years 9 months 7 days	6 years 11 months 5 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	2,903,188
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares	$ 3.31
Stock Options Exercised	0
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price \| $ / shares	$ 0.00
Stock Options Expired	(103,513)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price \| $ / shares	$ 6.52
Stock Options Forfeited	(302,450)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price \| $ / shares	$ 7.19
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	6,616,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price \| $ / shares	$ 7.00
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	7 years 8 months 9 days
Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest	1 year 7 months 24 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	4,726,752
Weighted average estimated fair value of shares granted \| $ / shares	$ 8.00
Options, Vested, weighted Average Remaining Contractual Term	7 years 1 month 13 days

Shareholders' Equity Restricted Stock (Details) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	1,276,053	456,709
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 4,029,500	$ 3,389,700
weighted average estimated fair value of restricted stock	$ 3.16	$ 7.42

Share-Based Compensation Share-Based Compensation (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 4,416,300	$ 1,759,700	$ 8,132,100	$ 5,653,500
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	4,979,600		$ 4,979,600
Expected weighted-average period in years of compensation cost to be recognized			3 years 3 months 15 days
Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 1,000		$ 1,000
Expected weighted-average period in years of compensation cost to be recognized			18 days
Total fair value of shares vested			$ 14,000	15,000
Weighted average estimated fair value of shares granted	$ 0.00		$ 0.00		$ 0.00
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average estimated fair value of shares granted	$ 2.17		$ 2.17		$ 4.92
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 401,200		$ 401,200
Expected weighted-average period in years of compensation cost to be recognized			2 years 11 months 5 days
Cost of revenue
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	378,200	98,500	$ 495,100	236,600
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	1,104,200	371,600	1,526,900	848,400
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 2,933,900	$ 1,289,600	6,110,100	4,568,500
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total fair value of shares vested			$ 4,915,300	$ 2,552,200

Research Funding - (Details) - Additional Funding Agreement Terms [Member] - Phase 3 Intus Study [Member]	1 Months Ended
	Jun. 30, 2015 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research funding, award amount	$ 17,725,734
Project initiation payment	3,000,000
Future operational milestone payments	$ 14,725,734

Income Taxes Net Operating Loss Carry Forward (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards					$ 177,200,000
Deferred Tax Liabilities, Net, Noncurrent	$ 14,519,460		$ 14,519,460		$ 18,176,190
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	9,400,000	$ 0	9,400,000	$ 0
Deferred Tax Liabilities, Deferred Expense	$ (3,700,000)		$ (3,700,000)

Commitments and Contingencies (Details)		3 Months Ended		6 Months Ended
Commitments and Contingencies (Details)	Feb. 19, 2015 USD ($) ft² renewal_term	Jun. 30, 2015 USD ($) ft²	Jun. 30, 2014 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)
Operating Leases, Future Minimum Payments Due [Abstract]
2015		$ 985,700		$ 985,700
2016		2,062,000		2,062,000
2017		1,863,800		1,863,800
2018		1,034,800		1,034,800
2019 and thereafter		1,949,600		1,949,600
Total minimum lease payments		7,895,900		7,895,900
Operating lease expense		$ 400,000	$ 300,000	800,000	$ 500,000
CALIFORNIA
Operating Leased Assets [Line Items]
Operating lease, additional space rented \| ft²		4,000
NEW JERSEY
Operating Leased Assets [Line Items]
Operating lease, rentable space \| ft²	18,000
Operating leases, monthly rental payments	$ 25,000
Operating leases, number of renewal terms \| renewal_term	2
Lessee leasing arrangements, operating leases, renewal term	5 years
Proceeds from lease assignment	$ 580,000
Security deposit liability		$ 115,000		$ 115,000